Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment

Journal of Cellular Biochemistry

Volumn 106, Issue 5, 2009, Pages 937-955

  Wȩsierska Ga̧dek, Józefa ^a,b   Borza, Andreea ^a   Walzi, Eva ^a   Krystof, Vladimir ^a   Maurer, Margarita ^a   Komina, Oxana ^a   Wandl, Stefanie ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Cell cycle arrest; Cyclin dependent kinases; Inhibitors of cyclin dependent kinases; Roscovitine

Indexed keywords

NOCODAZOLE; ROSCOVITINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

CELL CYCLE; CULTURE MEDIA, SERUM-FREE; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G1 PHASE; HELA CELLS; HUMANS; PURINES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 65349087936     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22074     Document Type: Article

References (58)

1. Abbas T, Jha S, Sherman NE, Dutta A. 2007. Autocatalytic phosphorylation of CDK2 at the activating Thr160. Cell Cycle 6:843-852.
2. Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala LA, Scovassi AI, Meijer L, Prosperi E. 1998. The cyclin-dependent kinase inhibitors olomoucine and
3. roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 activity. Exp Cell Res 245:8-18.
4. Altieri DC. 2003. Validating survivin as a cancer therapeutic target. Nat Rev 3:46-54.
5. Balsitis S, Dick F, Dyson N, Lambert PF. 2006. Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res 66:9393-9400.
6. Besson A, Dowdy SF, Roberts JM. 2008. CDK inhibitors: Cell cycle regulators and beyond. Dev Cell 14:159-169.
7. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. 2003. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683-2692.
8. Cai D, BythKF, Shapiro GI. 2006. AZ703, an imidazo[1, 2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 66:435- 444.
9. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. 2004. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014.
10. Dai Y, Grant S. 2003. Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 4:362-370.
11. Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. 2001. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: Induction of endoreplication following prophase arrest. Oncogene 20:3786-3797.
12. David-Pfeuty T. 1999. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 18:7409- 7422.
13. Fischer PM, Lane DP. 2000. Inhibitors of cyclin-dependent kinases as anticancer therapeutics. Curr Med Chem 12:1213-1245.
14. Fisher RP. 2005. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118:5171-5180.
15. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. 2004. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427-1438.
16. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. 1997. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11:2090- 2100.
17. Garrett S, Barton WA, Knights R, Jin P, Morgan DO, Fisher RP. 2001. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol Cell Biol 21:88-99.
18. Hajduch M, Havlicek L, Vesely J, Novotny R, Mihal V, Strnad M. 1999. Synthetic cyclin dependent kinase inhibitors. New generation of potent anticancer drugs. Adv Exp Med Biol 457:341-353.
19. Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ. 1999. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 3:413-422.
20. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M. 1997. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 40 (4) : 408-412.
21. Helt AM, Galloway DA. 2003. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159-169.
22. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF. 2008. Phosphorylation of retinoblastoma protein by viral protein with cyclindependent kinase function. Science 320:797-799.
23. Knockaert M, Lenormand P, Gray N, Schultz P, Pouyssegur J, Meijer L. 2002. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 21:6413-6424.
24. KrystofV, CankarP, FrysovaI, Slouka J, Kontopidis G, DzubakP, Hajduch M, Srovnal J, de Azevedo WF, Jr., Orság M, Paprskárová M, Rolcík J, Latr A, Fischer PM, Strnad M. 2006. 4-arylazo-3, 5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 49:6500-6509.
25. Lolli G, Lowe ED, Brown NR, Johnson LN. 2004. The crystal structure of human CDK7 and its protein recognition properties. Structure 12:2067-2079.
26. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE. 2004. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64:2840-2845.
27. Malumbres M, Barbacid M. 2005. Mammalian cyclin-dependent kinases. Trends Biochem Sci 30:630-641.
28. Malumbres M, Barbacid M. 2007. Cell cycle kinases in cancer. Curr Opin Genet Dev 17:60-65.
29. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. 2008. CDK inhibitors in cancer therapy: What is next? Trends Pharmacol Sci 29:16-21.
30. Matsumoto Y, Hayashi K, Nishida E. 1999. Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol 9:429-432.
31. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP. 2002. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102:463-468.
32. McLaughlin-Drubin ME, Huh KW, Münger K. 2008. The human papillomavirus type 16 E7 oncoprotein associates with E2F6. J Virol DOI: 10.1016 /j.virol.2008.10.006.
33. Nguyen DX, Westbrook TF, McCance DJ. 2002. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J Virol 76:619-632.
34. O'Connor DS, Grossman D, Plescia J, Li FZ, Zhang H, Tognin S, Marchisio PC, Altieri DC. 2000. Regulation of apoptosis at cell division by p34c c2 phosphorylation of survivin. Proc Natt Acad Sci USA 97:13103-13107.
35. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102:849-862.
36. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K 2000. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103:127-140.
37. Penuelas S, Alemany C, Noe V, Ciudad CJ. 2003. The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors. Eur J Biochem 270:4809-4822.
38. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P. 2005. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11:4875-4887.
39. Schang LM, Coccaro E, Lacasse JJ. 2005. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes. Nucleos Nucleot Nucl Acid 24:829-837.
40. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
41. Shapiro GI. 2006. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783.
42. Song Z, Yao X, Wu M. 2003. Direct interaction between survivin and Smac /DIABLO is essential for the anti-apoptotic activity of survivin during taxolinduced apoptosis. J Biol Chem 278:23130-23140.
43. Song Z, Liu S, He H, Hoti N, Wang Y, Feng S, WuM. 2004. A single amino acid change (Asp53-Ala53) converts survivin from antiapoptotic to proapoptotic. Mol Biol Cell 15:1287-1296.
44. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. 2000. Structure of the human anti-apoptotic protein survivin reveals a dimeric rearangement. Nat Struct Biol 7:602-608.
45. Vindelov LL, Christensen IJ, Nissen NI. 1983. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327.
46. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. 2003. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63:230-235.
47. Wesierska-Gadek J, Schmid G. 2000. Overexpressed poly (ADP-ribose) polymerase delays the release of rat cells from p53-mediated G (1) checkpoint. J Cell Biochem 80:85-103.
48. Wesierska-Gadek J, Schmid G. 2007b. Transcriptional repression of antiapoptotic proteins mediated by the tumor suppressor protein p53. Cancer Ther 5:203-212.
49. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. 2002. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 101:128-136.
50. Wesierska-Gadek J, Gueorguieva M, Horky M. 2005a. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 4:113-124. Wesierska-Gadek J, Gueorguieva M, Ranftler C, Zerza-Schnitzhofer G. 2005b. A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death. J Cell Biochem 96:1-7.
51. Wesierska-Gadek J, Schreiner T, Gueorguieva M, Ranftler C. 2006. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells. J Cell Biochem 98:1367-1379.
52. Wesierska-Gadek J, Gueorguieva M, Kramer MP, Ranftler C, Sarg B, Lindner H. 2007a. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: Up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem 102:1405-1419.
53. Wesierska-Gadek J, Schmitz ML, Ranftler C. 2007c. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 ar Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100:865-874.
54. Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E, Lindner H. 2008a. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Biochem Pharmacol 76:1503-1514.
55. Wesierska-Gadek J, Wandl S, Kramer M, Pickem C, Krystof V, Hajek SB. 2008b. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS3 cervix carcinoma cells. J Cell Biochem 105:1161-1171.
56. Whittaker SR, Walton MI, Garrett MD, Workman P. 2004. The cyclindependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogenactivated protein kinase pathway. Cancer Res 64:262-272.
57. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. 2003. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitineinduced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106:486-495.
58. Zaffaroni N, Pennati M, Daidone MP. 2005. Survivin as a target for new anticancer intervention. J Cell Mol Med 9:360-372.